 Shares of Aveo climbed 17 early Thursday, stretching their run higher after the company won US regulatory approval for its renal cancer treatment Fotivda. The stock on Wednesday soared 89 and was subject to two trading halts. Shares closed at 15.28. The two-day move higher came after the Food and Drug Administration on Wednesday approved the companys Fotivda treatment for adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies. 